Hong Kong-listed clinical stage biopharmaceutical firm Transcenta Holding Limited announces the appointment of Daniel Weng as the company's CFO.
As a member of the executive leadership team, Weng will be fully responsible for the company's financial strategy, performance reporting, capital markets activities, and investor relations, according to the firm.
Prior to Transcenta, he served as the vice president and Head of finance at Hong Kong-listed CStone Pharmaceuticals. He also had stints at Hong Kong-listed firm Everest Medicines as head of finance and Amgen as CFO of China.
Before Amgen, Daniel spent nearly 15 years as a senior and executive finance professional at MNCs such as GE, Honeywell in China, and other overseas companies.